Cary Street Partners Investment Advisory’s Biofrontera BFRI Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio BFRI Stock Details BFRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25	Closed	-$219	–	744
2023 Q3	$219	Buy	+25	New	+$244	﹤0.01%	1825

Other funds holding BFRI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cary Street Partners Investment Advisory's BFRI Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Biofrontera (BFRI) in Q4 2023, closing a stake of 25 shares — an estimated $219 sold.

Cary Street Partners Investment Advisory first reported a position in BFRI in Q3 2023 and held it in 1 quarter. The position peaked at $219 in Q3 2023. 8 funds tracked by Wall St. Rank hold BFRI as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Biofrontera position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 25 Biofrontera shares in Q4 2023, an estimated $219.
Cary Street Partners Investment Advisory first reported a position in Biofrontera in Q3 2023 and held it in 1 quarter.
Cary Street Partners Investment Advisory's Biofrontera position peaked at $219 in Q3 2023.
8 funds tracked by Wall St. Rank held Biofrontera as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.